5 Analysts Have This to Say About Reneo Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Reneo Pharmaceuticals (NASDAQ:RPHM) has received 5 analyst ratings in the last quarter, with 2 bullish and 3 indifferent. The average 12-month price target is $12.86, with a high of $30.00 and a low of $1.00. This target has decreased by 45.28% from the previous average of $23.50. Analyst ratings are opinions based on financial analysis and are meant to guide investors.

December 15, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Reneo Pharmaceuticals has a mixed outlook from analysts, with an average price target of $12.86, which is a significant decrease from the previous target.
The mixed analyst ratings with a majority being indifferent suggest a neutral short-term impact on RPHM's stock price. The significant decrease in the average price target could indicate a negative sentiment, but the presence of bullish ratings balances this view. The confidence level is not at the maximum due to the subjective nature of analyst ratings and the fact that they are opinions rather than guarantees.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100